XORTX Therapeutics Inc. - Common Stock (XRTX)
0.9210
-0.0390 (-4.06%)
NASDAQ · Last Trade: Apr 4th, 12:32 AM EDT
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
New York, NY - March 19, 2024 - In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
Via Get News · March 19, 2024
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
New York, NY, March 19, 2024 – (Plato Data) -- In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
Via TheNewswire.com · March 19, 2024